Taysha Gene Therapies highlights Phase 1/2 REVEAL trial data for TSHA-102 in Rett syndrome at Child Neurology Society meeting

By Public Technologies
  • Taysha Gene Therapies flagged new encore presentations on TSHA-102 for Rett syndrome at the Child Neurology Society meeting on Oct. 14-17, 2026.
  • Clinical findings were already presented at the 2026 International Rett Syndrome Foundation scientific meeting.
  • Disclosed results point to functional improvements across multiple domains in both pediatric and older patients, alongside an acceptable safety profile.
  • Updates draw from the REVEAL Part A Phase 1/2 trial, positioning TSHA-102 as the company’s lead CNS gene therapy program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010800PRIMZONEFULLFEED9837334) on October 01, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.